2022 Year in Review: Top News and Insights in Gene Therapy


Review some of our most-viewed coverage of advancements in gene therapies, including study data and clinical trial updates.

2022 was a big year for gene therapies, with FDA approvals coming in for indications including hemophilia B, transfusion-dependent beta-thalassemia, bladder cancer, and active cerebral adrenoleukodystrophy. With clinical trials for many more therapeutic areas underway, 2023 is shaping up to potentially offer even more advances in gene therapy.

CGTLive has brought you coverage of key advancements throughout the year, including the latest study data and clinical trial updates. Let's review some of our most-viewed coverage of gene therapies from 2022 below:

1. Running With Scissors: The FDA Moves to Tame Gene Therapy Drug Development

Looking to homogenize expectations around clinical trial design and execution, the FDA released 3 separate guidance documents in 2022 focused on the following topics: gene editing, gene therapy for neurodegenerative diseases, and gene therapy umbrella trials.

2. Stargardt Disease Gene Therapy IND Cleared to Proceed

Nanoscope Therapeutics received approval from the FDA for its investigational new drug (IND) application for MCO-010, a gene therapy for the potential treatment of Stargardt disease, a type of macular degeneration.

3. First Patient Dosed in Limb-Girdle Muscular Dystrophy Gene Therapy Trial

The first patient with FRKP-related limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) was treated with Atamyo Therapetuics’ ATA-100 (GNT0006), an investigational gene therapy, in a phase 1/2 clinical trial (EudraCT 2021-004276-33, NCT05224505).

4. Real-World Luxturna Data Shows Good Efficacy, New Adverse Reaction in Retinal Dystrophy

Findings from the ongoing PERCEIVE study demonstrated continued safety and efficacy of voretigene neparvovec (Luxturna; Spark Therapeutics) in patients with RPE65-mediated inherited retinal dystrophy in the real-world setting. The findings, which included up to 2 years of data, were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, and also shed light on a new treatment-related adverse reaction.

5. Improvements in Developmental Milestones Observed With GM1 Gangliosidosis Gene Therapy

Data from the ongoing Imagine-1 clinical trial (NCT04713475) demonstrated good safety and impressive improvements in clinically meaningful end points in patients with GM1 gangliosidosis treated with PBGM01, an investigational gene therapy from Passage Bio.

Recent Videos
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
© 2024 MJH Life Sciences

All rights reserved.